Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer?

Cancer ◽  
2007 ◽  
Vol 109 (10) ◽  
pp. 2093-2099 ◽  
Author(s):  
A. Tyler Watlington ◽  
Tim Byers ◽  
Judy Mouchawar ◽  
Angela Sauaia ◽  
Jenn Ellis
2017 ◽  
Vol 166 (1) ◽  
pp. 195-195 ◽  
Author(s):  
María Elena Martínez ◽  
Scarlett L. Gomez ◽  
Li Tao ◽  
Rosemary Cress ◽  
Danielle Rodriguez ◽  
...  

2007 ◽  
Vol 18 (4A) ◽  
pp. 130-145 ◽  
Author(s):  
María Elena. Martínez ◽  
Carrie M. Nielson ◽  
Ray. Nagle ◽  
Ana Maria. Lopez ◽  
Christina. Kim ◽  
...  

2014 ◽  
Author(s):  
Avonne E. Connor ◽  
Kathy B. Baumgartner ◽  
Richard N. Baumgartner ◽  
Christina M. Pinkston ◽  
Stephanie D. Boone ◽  
...  

2020 ◽  
pp. OP.20.00381
Author(s):  
Cosette D. Champion ◽  
Samantha M. Thomas ◽  
Jennifer K. Plichta ◽  
Edgardo Parrilla Castellar ◽  
Laura H. Rosenberger ◽  
...  

PURPOSE: We sought to examine tumor subtype, stage at diagnosis, time to surgery (TTS), and overall survival (OS) among Hispanic patients of different races and among Hispanic and non-Hispanic (NH) women of the same race. METHODS: Women 18 years of age or older who had been diagnosed with stage 0-IV breast cancer and who had undergone lumpectomy or mastectomy were identified in the National Cancer Database (2004-2014). Tumor subtype and stage at diagnosis were compared by race/ethnicity. Multivariable linear regression and Cox proportional hazards modeling were used to estimate associations between race/ethnicity and adjusted TTS and OS, respectively. RESULTS: A total of 44,374 Hispanic (American Indian [AI]: 79 [0.2%]; Black: 1,011 [2.3%]; White: 41,126 [92.7%]; Other: 2,158 [4.9%]) and 858,634 NH women (AI: 2,319 [0.3%]; Black: 97,206 [11.3%]; White: 727,270 [84.7%]; Other: 31,839 [3.7%]) were included. Hispanic Black women had lower rates of triple-negative disease (16.2%) than did NH Black women (23.5%) but higher rates than did Hispanic White women (13.9%; P < .001). Hispanic White women had higher rates of node-positive disease (23.2%) versus NH White women (14.4%) but slightly lower rates than Hispanic (24.6%) and NH Black women (24.5%; P < .001). Hispanic White women had longer TTS versus NH White women regardless of treatment sequence (adjusted means: adjuvant chemotherapy, 42.71 v 38.60 days; neoadjuvant chemotherapy, 208.55 v 201.14 days; both P < .001), but there were no significant racial differences in TTS among Hispanic patients. After adjustment, Hispanic White women (hazard ratio, 0.77 [95% CI, 0.74 to 0.81]) and Black women (hazard ratio, 0.75 [95% CI, 0.58 to 0.96]) had improved OS versus NH White women (reference) and Black women (hazard ratio, 1.15 [95% CI, 1.12 to 1.18]; all P < .05). CONCLUSION: Hispanic women had improved OS versus NH women, but racial differences in tumor subtype and nodal stage among Hispanic women highlight the importance of disaggregating racial/ethnic data in breast cancer research.


Cancer ◽  
2010 ◽  
Vol 116 (13) ◽  
pp. 3215-3223 ◽  
Author(s):  
Lisa M. Hines ◽  
Betsy Risendal ◽  
Martha L. Slattery ◽  
Kathy B. Baumgartner ◽  
Anna R. Giuliano ◽  
...  

2012 ◽  
Vol 136 (2) ◽  
pp. 593-602 ◽  
Author(s):  
Avonne E. Connor ◽  
Richard N. Baumgartner ◽  
Kathy B. Baumgartner ◽  
Richard A. Kerber ◽  
Christina Pinkston ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document